Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is Safe and Efficacious in Recurrent and Advanced Ovarian Cancer

Chunmeng Zhang
University of Nebraska Medical Center

Ryan Mikus
University of Nebraska Medical Center

Dalton Hegeholz
University of Nebraska Medical Center

Valerie Shostrom
University of Nebraska Medical Center

Abraham Matthews
Creighton University

See next page for additional authors

Tell us how you used this information in this short survey.
Follow this and additional works at: https://digitalcommons.unmc.edu/gmerj

Part of the Higher Education Commons, and the Medicine and Health Sciences Commons

Recommended Citation
https://digitalcommons.unmc.edu/gmerj/vol2/iss1/32

This Conference Proceeding is brought to you for free and open access by DigitalCommons@UNMC. It has been accepted for inclusion in Graduate Medical Education Research Journal by an authorized editor of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.
Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is Safe and Efficacious in Recurrent and Advanced Ovarian Cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Authors
Chunmeng Zhang, Ryan Mikus, Dalton Hegeholz, Valerie Shostrom, Abraham Matthews, James Commers, Laura Lambert, and Jason Foster

This conference proceeding is available in Graduate Medical Education Research Journal: https://digitalcommons.unmc.edu/gmerj/vol2/iss1/32
Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Is Safe and Efficacious in Recurrent and Advanced Ovarian Cancer
Chunmeng Zhang1, Ryan Mikus2, Dalton Hegeholz2, Valerie Shostrom1, Abraham Matthews4, James Commers4, Laura Lambert5, Jason Foster1
1University of Nebraska Medical Center, Department of Surgery
2University of Nebraska Medical Center, College of Medicine
3University of Nebraska Medical Center, College of Public Health, Department of Biostatistics
4Creighton University, Department of Hematology and Oncology
5University of Utah, Department of Surgery

Mentor: Jason Foster

Program: General Surgery

Type: Original Research

Background: HIPEC with cisplatin in recurrent and advanced ovarian cancer (AOC) improves survival, but renal toxicity is common, even with renal protectants. Carboplatin intravenous (IV) and intraperitoneal (IP) have significantly less nephrotoxicity with comparable efficacy. This study reports the safety and efficacy of carboplatin HIPEC for recurrent and AOC.

Methods: Retrospective analysis of a cytoreductive surgery (CRS) /HIPEC registry was performed on recurrent and AOC patients treated between 2012-2018 with and without HIPEC. HIPEC with carboplatin (600-800 mg/m2) was delivered for 90 minutes at 41-42 C. Peritoneal Cancer Index (PCI), Completeness of Cytoreduction (CC)-score, nephrotoxicity by RIFLE score, thrombocytopenia, pancytopenia, length of stay (LOS), progression free survival (PFS), overall survival (OS), peritoneal relapse and all relapse events were collected and compared from the date of surgery.

Results: A total of 34 recurrent and AOC patients had CRS, 21 treated with HIPEC. Mean PCI for CRS and CRS/HIPEC was 23 and 22 respectively. 95% HIPEC and 100% no HIPEC had R0/R1/R2a. 9% developed >grade 1 AKI. Thrombocytopenia (platelet < 75K) occurred in 23% of HIPEC patients. LOS was 9.5 days for both groups. Post-CRS OS was 15 vs. 56 months for CRS vs. CRS/ HIPEC, p<0.01. There was no difference in median OS in HIPEC group treated at recurrence or first CRS. Peritoneal recurrence was 69% for CRS vs 19% for CRS/HIPEC, p<0.01.

Conclusion: This data demonstrates that Carboplatin HIPEC has similar efficacy to cisplatin without the nephrotoxicity. Carboplatin HIPEC for recurrent and AOC is safe and efficacious. The survival benefit may be attributable to peritoneal disease control and peritoneal relapse free survival may be a viable endpoint in future HIPEC clinical trials.

https://doi.org/10.32873/unmc.dc.gmerj.2.1.031

Table 1.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) group demonstrates increased overall survival (OS), reduced rate of peritoneal relapse, and similar overall relapse rate when compared with non-HIPEC group. Upfront HIPEC is associated with lower peritoneal relapse rate when compared with HIPEC performed after disease recurrence.

<table>
<thead>
<tr>
<th>GROUP</th>
<th>#</th>
<th>OSCRS months</th>
<th>DOD (n=34)</th>
<th>NED (n=34)</th>
<th>PERITONEAL RELAPSE</th>
<th>ANY RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td>34</td>
<td>34</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>No HIPEC</td>
<td>13</td>
<td>20</td>
<td>73%</td>
<td>0%</td>
<td>69%</td>
<td>87%</td>
</tr>
<tr>
<td>HIPEC</td>
<td>21</td>
<td>56</td>
<td>42%</td>
<td>38%</td>
<td>19%</td>
<td>70%</td>
</tr>
<tr>
<td>HIPEC recurrent</td>
<td>9</td>
<td>56</td>
<td>33%</td>
<td>15%</td>
<td>33%</td>
<td>92%</td>
</tr>
<tr>
<td>HIPEC upfront</td>
<td>12</td>
<td>56</td>
<td>23%</td>
<td>58%</td>
<td>8%</td>
<td>67%</td>
</tr>
</tbody>
</table>

Exploring Head and Neck (H&N) Melanoma Sentinel Lymph Node (SLN) Outcome Compliance With Multicenter Selective Lymphadenectomy Trials (MSLT) Predicted Outcome
Chunmeng Zhang1, Srinivasa Rama Chandra2, Maggie Moore3, Dominick DiMaio3, Valerie Shostrom1, Ujwal Yanala1, Edibaldo Silva-Lopez1, Jason Foster1
1University of Nebraska Medical Center, Department of Surgery
2University of Nebraska Medical Center, College of Medicine
3University of Nebraska Medical Center, Department of Pathology and Microbiology
4University of Nebraska Medical Center, College of Public Health, Department of Biostatistics
5University of Nebraska Medical Center, Department of Public Health, Department of Biostatistics
6Creighton University, Department of Hematology and Oncology

Mentor: Jason Foster

Program: General Surgery

Type: Original Research

Background: MSLT II. This project explored the validity of observations reported in MSLT II in H&N melanoma.

Methods: Retrospective H&N melanoma population treated 2005-2019. 124 ≥T1b with SLN injection and 108 SLN dissections were performed. Complication rates, T-stage, rates of +SLN, +NSLN in CLND were calculated, as well as death due to disease (DOD), progression free survival (PFS), along with rates of local (LR), nodal (LNR), and systemic (SR) recurrence.

Results: T-stage was 41% IB, 23% IIA, 28% IIB, 8% IIC. Nerve complication was 4% for SLN and 11% for CLND. +SLN rate was 2-fold higher and +NSLN following CLND was 3-fold higher in H&N melanoma. Local regional recurrence rates were higher for CLND compared to SLN+ only. These results support nodal survival is 93% compare to survival of 70% for +SLN group with median follow-up of 40 months. Rate of +SLN was 29% and +NSLN rate for CLND was 50%. Patients with positive SLN but did not undergo CLND (+SLNBx only) has surprisingly lower rate of LR, LNR, SR, and DOD when compared to patients with positive SLN who underwent CLND (CLND group). (Table 1.)

Conclusion: +SLN rate was 2-fold higher and +NSLN following CLND was 3-fold higher in H&N melanoma. Local regional recurrence rates were higher for CLND compared to SLN+ only. These results support nodal